The Ocular Genomics Institute at Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
J Pathol. 2021 Oct;255(2):120-131. doi: 10.1002/path.5747. Epub 2021 Jul 27.
Despite numerous unsuccessful clinical trials for anti-complement drugs to treat age-related macular degeneration (AMD), the complement system has not been fully explored as a target to stop drusen growth in patients with dry AMD. We propose that the resilient autoactivation of C3 by hydrolysis of its internal thioester (tick-over), which cannot be prevented by existing drugs, plays a critical role in the formation of drusenoid deposits underneath the retinal pigment epithelium (RPE). We have combined gene editing tools with stem cell technology to generate cell-based models that allow the role of the tick-over in sub-RPE deposit formation to be studied. The results demonstrate that structurally or genetically driven pathological events affecting the RPE and Bruch's membrane can lead to dysregulation of the tick-over, which is sufficient to stimulate the formation of sub-RPE deposits. This can be prevented with therapies that downregulate C3 expression. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
尽管针对抗补体药物治疗年龄相关性黄斑变性(AMD)进行了多次不成功的临床试验,但补体系统尚未作为阻止干性 AMD 患者玻璃膜疣生长的靶点进行充分研究。我们提出,C3 通过其内部硫酯键(滴答声)的水解进行弹性自动激活,这是现有药物无法预防的,在视网膜色素上皮(RPE)下的类脂斑沉积物的形成中起着关键作用。我们将基因编辑工具与干细胞技术相结合,生成基于细胞的模型,使滴答声在 RPE 下沉积物形成中的作用能够得到研究。结果表明,结构或遗传驱动的影响 RPE 和布鲁赫膜的病理性事件可导致滴答声失调,足以刺激 RPE 下沉积物的形成。通过下调 C3 表达的治疗可以预防这种情况。2021 年,英国和爱尔兰病理学学会。由 John Wiley & Sons,Ltd. 出版。